

Average Proteinuria Grade Combined SLE Experiments +/- SEM




FIGURE 1

Dosing Protocol

SLE-5	Treatment, 3x/wk, Subcutaneously	Age (weeks)																	
		25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40		
A	5 mg/kg Rapamycin (AY-22989-21)	→																	
B	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
C	5 mg/kg Rapamycin (AY-22989-21)	→																	
	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
D	5 mg/kg Rapamycin (AY-22989-21)	→																	
E	5 mg/kg Rapamycin (AY-22989-21)	→																	
	200 ug/ms anti-murine B7.1	→																	
	200 ug/ms anti-murine B7.2	→																	
F	200 ug/ms anti-murine IL-12	→																	
G	Vehicle	→																	

FIGURE 2

97 JPS-002 SLE-7 Histopathologic Evaluation of NZB x NZW F1 Hybrid Female Mice

42 weeks of age

Group	Animal	Spleen	Spleen	Kidney	Kidney	Kidney
No Therapy		Lymphoid Hyperplasia	Hematopoiesis	Interstitial Inflammation	Glomerulonephritis Cellularity- Membrane Thickness	Tubular Dilatation
	1	- 2	- 3	+ 2	- 2	+ 2
	2	+ 2	+ 2	+ 3	- 1	+ 3
	3	+ 2	+ 2	+ 2	- 1	+ 3
	4	+ 2	+ 2	+ 3	- 3	+ 3
	5	+ 2	+ 3	+ 3	- 3	+ 3
	<u>Mean</u>	+ 1.2	+ 1.2	+ 2.6	- 2.0	+ 2.8

Rapamycin
(Treatment Weeks 29-36)

1	+ 1	+ 1	(+ 1)	0	+ 1	+ 1
2	+ 1	+ 1	(+ 1)	0	+ 1	0
3	+ 1	+ 1	(+ 2)	0	0	0
4	+ 1	+ 1	0	0	0	0
5	+ 1	+ 1	(+ 1)	0	0	0
<u>Mean</u>	+ 1.0	+ 1.0	+ 1.0	0	+0.4	+ 0.2


Histologic Grades

- 0 = Normal
- 1 = Slight
- 2 = Mild
- 3 = Moderate
- 4 = Marked
- 5 = Severe
- () = Focal not Diffuse

Histopathologic Assessment : Elizabeth Goad, PhD, DVM.

FIGURE 3

A. Survival (SLE-5)



Early Rapamycin given
beginning @ 25 weeks old,

Late Rapamycin given
beginning @ 33 weeks old.

FIGURE 4A

B. Average Proteinuria Grade




FIGURE 4B

A.

Single Therapeutic Dosing




FIGURE 5A

B.

Combined Therapeutic Dosing




FIGURE 5B